Prognostic effect of systemic immune-inflammation index (SII) in 987 patients with advanced/metastatic urinary tract carcinoma (mUTC) treated with atezolizumab in the real-world global SAUL study

Autor:	Mego, M., Huddart, R. A., Voortman, J., Ong, M., Gedye, C., Gurney, H., Fay, A. P., Bamias, A., Mellado Gonzalez, B., Loriot, Y., Merseburger, A. S., Castellano Gauna, D., de Ducla, S., Pavlova, J., Fear, S., Sternberg, C. N.
Přispěvatelé:	Internal medicine, CCA - Imaging and biomarkers, CCA - Treatment and quality of life
Jazyk:	angličtina
Rok vydání:	2020
Zdroj:	Annals of Oncology, 31, S591-S591. Oxford University Press Mego, M, Huddart, R A, Voortman, J, Ong, M, Gedye, C, Gurney, H, Fay, A P, Bamias, A, Mellado Gonzalez, B, Loriot, Y, Merseburger, A S, Castellano Gauna, D, de Ducla, S, Pavlova, J, Fear, S & Sternberg, C N 2020, ' Prognostic effect of systemic immune-inflammation index (SII) in 987 patients with advanced/metastatic urinary tract carcinoma (mUTC) treated with atezolizumab in the real-world global SAUL study ', Annals of Oncology, vol. 31, pp. S591-S591 . https://doi.org/10.1016/j.annonc.2020.08.838
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2020.08.838
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::24d6545c8ec7c5acc66ba6e2ec8909b4 https://research.vumc.nl/en/publications/87c55a6e-4faf-48ed-aea2-27cb08420fe9 Zobrazit plný text záznamu